Trevi Therapeutics’ (TRVI) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a research report released on Friday,Benzinga reports. D. Boral Capital currently has a $21.00 target price on the stock.

Other equities analysts also recently issued reports about the company. HC Wainwright raised their price objective on Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a research note on Thursday, December 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a research note on Thursday, December 12th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $9.31.

Trevi Therapeutics Price Performance

NASDAQ TRVI opened at $4.30 on Friday. Trevi Therapeutics has a 1-year low of $2.30 and a 1-year high of $5.05. The company has a market capitalization of $330.52 million, a P/E ratio of -9.77 and a beta of 0.90. The business has a 50 day moving average price of $4.14 and a 200 day moving average price of $3.51.

Institutional Investors Weigh In On Trevi Therapeutics

Hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its holdings in shares of Trevi Therapeutics by 220.6% during the third quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company’s stock worth $336,000 after purchasing an additional 69,167 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Trevi Therapeutics by 10.2% during the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock worth $4,223,000 after purchasing an additional 117,418 shares during the last quarter. Barclays PLC boosted its holdings in shares of Trevi Therapeutics by 180.8% during the third quarter. Barclays PLC now owns 95,232 shares of the company’s stock worth $319,000 after purchasing an additional 61,317 shares during the last quarter. State Street Corp boosted its holdings in shares of Trevi Therapeutics by 5.9% during the third quarter. State Street Corp now owns 952,912 shares of the company’s stock worth $3,183,000 after purchasing an additional 53,051 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Trevi Therapeutics by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after purchasing an additional 6,764 shares during the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.